Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.13 USD | -1.07% | -13.92% | +79.90% |
14/05 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
13/05 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.90% | 29Cr | |
+59.34% | 6.26TCr | |
-2.64% | 4.12TCr | |
+44.25% | 4.03TCr | |
-8.29% | 2.79TCr | |
+12.68% | 2.62TCr | |
-21.73% | 1.91TCr | |
+5.95% | 1.31TCr | |
+24.29% | 1.23TCr | |
+27.24% | 1.21TCr |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- Inovio Pharmaceuticals Says Trial Data Shows INO-3107 for Papillomatosis Is Well Tolerated, Reduces Surgery